Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

More articles from Pharmacokinetics and Pharmacodynamics

  • Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
    Albert A Antolin, Malaka Ameratunga, Udai Banerji, Paul Clarke, Paul Workman, Bissan Al-Lazikani
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C01; DOI: 10.1158/1535-7163.TARG-19-LB-C01
  • Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
    Rosemarie de Haan, Dick Pluim, Manon Verwijs, Gabe Sonke, Michel van den Heuvel, Baukelien van Triest, Marcel Verheij, Conchita Vens
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C009; DOI: 10.1158/1535-7163.TARG-19-C009
  • Abstract B085: Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor
    Deborah Knoerzer, Martin Teresk, Peter Krutzik, Erika O’Donnell, Gary DeCrescenzo, Dean Welsch, Caroline Emery
    Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B085; DOI: 10.1158/1535-7163.TARG-17-B085
  • Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation
    William G. Herrick, Casey L. Kilpatrick, Melinda Hollingshead, James H. Doroshow, Ralph E. Parchment, Apurva K. Srivastava
    Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B081; DOI: 10.1158/1535-7163.TARG-17-B081
  • Abstract B082: Evaluation of the effects of an oral Notch inhibitor, LY3039478, on QT interval, and absolute and pilot relative bioavailability studies conducted in healthy subjects
    Eunice Yuen, Maria Posada, Claire Smith, Katharine Thorn, Dale Greenwood, Michelle Burgess, Karim Benhadji, Demetrio Ortega, Louise Chinchen, Jeffrey Suico
    Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B082; DOI: 10.1158/1535-7163.TARG-17-B082
  • Abstract B084: Preclinical pharmacokinetic evaluation of alofanib for cancer treatment
    Ilya Tsimafeyeu, Mikhail Byakhov, Vlatka Bencetić Mihaljević, Jasna Padovan, Genoveva Murillo, Nadezhda Dragun, Evgenia Gavrilova, Sergei Tjulandin
    Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B084; DOI: 10.1158/1535-7163.TARG-17-B084
  • Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
    Eunice Yuen, Robert Bell, Maria Posada, Christophe Massard, Jordi Rodon, Claire Smith, Katharine Thorn, JT Diener, Demetrio Ortega, Jeffrey Suico, Karim Benhadji
    Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B083; DOI: 10.1158/1535-7163.TARG-17-B083
  • Abstract B150: Identifying tolerable schedules for targeted anti-cancer agents by applying ordered logistic regression modeling to empirical pathology scores in mice
    Francis Gibbons, Shenghua Wen, Prasad Nadella
    Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) B150; DOI: 10.1158/1535-7163.TARG-15-B150
  • Abstract B149: Clinical pharmacokinetics (PK) of an anti-epidermal growth factor receptor (EGFR) antibody drug conjugate (ADC), ABT-414, in patients with glioblastoma multiforme (GBM) or advanced solid tumors likely to overexpress EGFR: Results from phase 1 studies
    Rajendar K. Mittapalli, Wijith P. Munasinghe, Zaw-Myo-Htet F. Myasein, David M. Hoffmann, Rose K. Lai, Kyle D. Holen, Hao Xiong
    Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) B149; DOI: 10.1158/1535-7163.TARG-15-B149
  • Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model
    Christophe Henry, Céline Nicolazzi, Céline Amara, Anne-Marie Lefebvre, Christelle Larois, Florence Attenot, Claire Brillac, Marion Bouillon-Pichault, Nathalie Fagniez, Stéphanie Decary, Cécile Combeau, Pierre-François Berne, Souâd Naimi, Marielle Chiron, Véronique Blanc
    Molecular Cancer Therapeutics Dec 2015, 14 (12 Supplement 2) B145; DOI: 10.1158/1535-7163.TARG-15-B145

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 11
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement